Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Operates in Pharma — Production. Per the activity note to the FY2024 annual report, the company manufactures pharmaceutical products and provides healthcare-related services. Founded in 2016.
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|
| 2,400 | 2,780 | 2,891 | 3,190 | 2,843 | 3,144 | 1,413 | -8.5% | |
| Total COGS | 772 | 1,222 | 1,338 | 1,258 | 961 | 1,157 | 586 | -4.5% |
| Gross Profit | 1,628 | 1,557 | 1,553 | 1,932 | 1,881 | 1,987 | 827 | -10.7% |
| Gross Margin | 67.8% | 56.0% | 53.7% | 60.6% | 66.2% | 63.2% | 58.5% | |
| 773 | 780 | 355 | 838 | 921 | 1,512 | 722 | -1.1% | |
| EBITDA | 855 | 778 | 1,198 | 1,094 | 960 | 475 | 104 | -29.6% |
| EBITDA Margin | 35.6% | 28.0% | 41.4% | 34.3% | 33.8% | 15.1% | 7.4% | |
| Total D&A | 91 | 73 | 79 | 122 | 115 | 103 | 85 | -1.1% |
| EBIT / Operating Income | 764 | 705 | 1,118 | 972 | 846 | 372 | 19 | -45.8% |
| Total Interest Income | 1 | 0 | 0 | 0 | 4 | 7 | 10 | +59.9% |
| 64 | 1 | 610 | 540 | 342 | 234 | 80 | +3.9% | |
| Profit Before Tax | 828 | 704 | 1,728 | 1,512 | 1,192 | 612 | 109 | -28.6% |
| Total Income Tax | 81 | 77 | 75 | 86 | 129 | 124 | 142 | +9.9% |
| Net Profit / (Loss) | 774 | 700 | 1,093 | 984 | 656 | 317 | 33 | nmf |
| Net Margin | 32.2% | 25.2% | 37.8% | 30.9% | 23.1% | 10.1% | 2.3% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →